Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Orlando Santana

Psychiatry Hialeah, FL Medical Doctor

NPI 1831249390 CMS profile 218790

4175 W 20Th Ave, Hialeah, FL 33012

Open in the dashboard

General payments

$4,915

225 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Orlando Santana of Hialeah, FL is reported in the CMS Open Payments database as having received $4,915 across 225 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 88th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,593 72
2024 General $1,454 63
2023 General $1,225 57
2022 General $568 29
2021 General $16 1
2019 General $58 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Orlando Santana
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Orlando Santana were reported at $1,593. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Orlando Santana Psychiatry median Middle half National median
2019 $58 $184 $59–$605 $163
2020 $0 $119 $36–$372 $114
2021 $16 $143 $43–$576 $132
2022 $568 $153 $50–$590 $149
2023 $1,225 $170 $56–$651 $160
2024 $1,454 $179 $57–$673 $164
2025 $1,593 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alkermes, Inc. $797 39 payments
  2. Otsuka America Pharmaceutical, Inc. $793 37 payments
  3. Janssen Pharmaceuticals, Inc $522 20 payments
  4. AbbVie, Inc. $480 27 payments
  5. Teva Pharmaceuticals USA, Inc. $466 20 payments
  6. Neurocrine Biosciences, Inc. $465 20 payments
  7. ITI, Inc. $325 14 payments
  8. E.R. Squibb & Sons, L.L.C. $304 14 payments
  9. Almatica Pharma LLC $254 12 payments
  10. Vanda Pharmaceuticals Inc. $185 7 payments
  11. Other $323 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,915 225 payments
Products named General payments · program years 2019–2025
  1. LYBALVI $732 36 payments
  2. ARISTADA Cns $674 33 payments
  3. ARISTADA Cns $674 33 payments
  4. INVEGA SUSTENNA $522 20 payments
  5. ARISTADA Cns $511 24 payments
  6. ARISTADA Cns $511 24 payments
  7. REXULTI $503 24 payments
  8. INGREZZA $465 20 payments
  9. VRAYLAR $316 17 payments
  10. LOREEV XR $254 12 payments
  11. Other $3,477 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 86 drugs

Part D claims

19,734

Median for Psychiatry & Neurology: 100

Drug cost

$1,390,513

Median for Psychiatry & Neurology: $2,986

Branded share of claims

10.9%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 31 $215,212
Invega Sustenna Paliperidone Palmitate Brand 62 $165,988
Rexulti Brexpiprazole Brand 119 $163,994
Abilify Maintena Aripiprazole Brand 36 $83,693
Vraylar Cariprazine Hcl Brand 57 $83,415
Aristada Aripiprazole Lauroxil Brand 30 $63,675
Aripiprazole Generic 531 $57,069
Fanapt Iloperidone Brand 33 $47,744
Lybalvi Olanzapine/Samidorphan Malate Brand 27 $42,517
Lurasidone Hcl Generic 159 $38,347

The 10 drugs with the highest cost, of 86 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 15 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $237
$237 31 —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $186
$186 62 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $119
  • Lundbeck LLC $54
$173 119 —
VRAYLAR
  • AbbVie, Inc. $141
$141 57 —
CAPLYTA
  • ITI, Inc. $128
$128 15 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 15 in the dashboard with a free account

Records

225 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record